Rigel Pharmaceuticals, Inc. (RIGL) — Analyst outlook / Analyst consensus target is. Based on 15 analyst ratings, the consensus is bullish — 8 Buy, 7 Hold.
The consensus price target is $40.00 (low: $38.00, high: $42.00), representing an upside of 27.4% from the current price $31.39.
Analysts estimate Earnings Per Share (EPS) of $0.39 and revenue of $0.17B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.99 vs est $0.39 (beat +154.5%). 2025: actual $20.40 vs est $6.64 (beat +207.3%). Analyst accuracy: 36%.
RIGL Stock — 12-Month Price Forecast
$40.00
▲ +27.43% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for Rigel Pharmaceuticals, Inc., the average price target is $40.00, with a high forecast of $42.00, and a low forecast of $38.00.
The average price target represents a +27.43% change from the last price of $31.39.
Highest Price Target
$42.00
Average Price Target
$40.00
Lowest Price Target
$38.00
RIGL Analyst Ratings
Buy
Based on 15 analysts giving stock ratings to Rigel Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — RIGL
36%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.99
vs Est $0.39
▲ 60.7% off
2025
Actual $20.40
vs Est $6.64
▲ 67.5% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is improving.
Revenue Estimates — RIGL
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.179B
vs Est $0.172B
▲ 4.2% off
2025
Actual $0.294B
vs Est $0.293B
▲ 0.4% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
